Literature DB >> 8097654

2-Chlorodeoxyadenosine: a new nucleoside agent effective in the treatment of lymphoid malignancies.

A Saven1, L D Piro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8097654     DOI： 10.3109/10428199309149111

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  5 in total

1.  A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors.

Authors:  G R Weiss; J G Kuhn; J Rizzo; L S Smith; G I Rodriguez; J R Eckardt; H A Burris; S Fields; K VanDenBerg; D D von Hoff
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 2.  Clinical and toxicological aspects of the antineoplastic drug cladribine: a review.

Authors:  H J Guchelaar; D J Richel; M R Schaafsma
Journal:  Ann Hematol       Date:  1994-11       Impact factor: 3.673

Review 3.  Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?

Authors:  Mukundan Baskar Mannargudi; Subrata Deb
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-17       Impact factor: 4.322

4.  Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL).

Authors:  Marco Montillo; Francesca Ricci; Sara Miqueleiz; Alessandra Tedeschi; Enrica Morra
Journal:  Biologics       Date:  2008-03

Review 5.  New insights into the synergism of nucleoside analogs with radiotherapy.

Authors:  Michael W Lee; William B Parker; Bo Xu
Journal:  Radiat Oncol       Date:  2013-09-26       Impact factor: 3.481
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.